Displaying 21 - 40 of 47
FTC Releases Interim Staff Report on Prescription Drug Middlemen
Date
The Federal Trade Commission today published an interim report on the prescription drug middleman industry that underscores the impact pharmacy benefit managers (PBMs) have on the accessibility and...
Statement of Chair Lina M. Khan Regarding the Policy Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports
Date
By
Lina M. Khan, Former Chair and Commissioner
FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy
Date
The Federal Trade Commission voted to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit mangers (PBMs) that no longer reflect current...
FTC Announces Tentative Agenda for July 20 Open Commission Meeting
Date
Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Thursday, July 20, 2023. The open meeting will commence at 11am ET and...
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
Date
As part of its ongoing study on pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued a compulsory...
FTC Deepens Inquiry into Prescription Drug Middlemen
Date
As part of its ongoing inquiry into pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued compulsory...
FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs
Date
The Federal Trade Commission announced that it will ramp up enforcement against any illegal bribes and rebate schemes that block patients’ access to competing lower-cost drugs. The enforcement policy...
Public Statement
Oral Remarks of Christine S. Wilson at Open Commission Meeting on June 16, 2022
Date
Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
Date
By
Alvaro Bedoya, Former Commissioner
Matter Number
P221201
Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding 6(b) Study of Pharmacy Benefit Managers
Date
By
Noah Joshua Phillips, Former Commissioner;
Christine S. Wilson, Former Commissioner
Matter Number
P221200
FTC Launches Inquiry Into Prescription Drug Middlemen Industry
Date
The Federal Trade Commission announced today that it will launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers to provide information...
Statement of Commissioner Rebecca Kelly Slaughter Regarding 6(b) Study of Pharmacy Benefit Managers
Date
By
Rebecca Kelly Slaughter, Former Commissioner
Matter Number
P221200
Federal Trade Commission Extends Public Comment Period for Request for Information on Impact of Pharmacy Benefit Managers
Date
The Federal Trade Commission is extending the public comment period, until May 25, 2022, on a request for information that covers a wide range of issues in the PBM market – including contract terms...
FTC Requests Public Comments on the Impact of Pharmacy Benefit Managers’ Practices
Date
The Federal Trade Commission announced it is soliciting public input on the ways that practices by large, vertically integrated Pharmacy Benefit Managers’ (PBMs) are affecting drug affordability and...
FTC Staff Comment Says New York Bill to Regulate Pharmacy Benefit Managers May Increase Pharmaceutical Prices for New York Consumers; Commission Approves Final Consent Order in Matter of Dow Chemical Company and Rohm & Haas Company
Date
FTC Staff Comment Says New York Bill to Regulate Pharmacy Benefit Managers May Increase Pharmaceutical Prices for New York Consumers – Federal Trade Commission staff filed a comment stating that...
Displaying 21 - 40 of 47